Evidence map›Paper›PMID 34920254›Full record

ArticleTalanta2022

Rapid electrochemical immunodetection of SARS-CoV-2 using a pseudo-typed vesicular stomatitis virus model.

Idan Ashur, Joel Alter, Michal Werbner, Abraham Ogungbile, Moshe Dessau, Meital Gal-Tanamy, Sefi Vernick

Open access · greenAbstract read
In one paragraph

Article in Talanta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Idan AshurDepartment of Sensing, Information and Mechanization Engineering, Institute of Agricultural Engineering, ARO Volcani Center, 68 Hamaccabim Rd, Rishon lezion, 5025001, Israel. Electronic address: idana@volcani.agri.gov.il.
Joel AlterThe Laboratory of Structural Biology of Infectious Diseases, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Electronic address: yoel.alter@biu.ac.il.
Michal WerbnerMolecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Electronic address: michal.poran@gmail.com.
Abraham OgungbileDepartment of Sensing, Information and Mechanization Engineering, Institute of Agricultural Engineering, ARO Volcani Center, 68 Hamaccabim Rd, Rishon lezion, 5025001, Israel; Department of Soil and Water Sciences, Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot, 761001, Israel. Electronic address: abraham.ogungbile@mail.huji.ac.il.
Moshe DessauThe Laboratory of Structural Biology of Infectious Diseases, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Electronic address: moshe.dessau@biu.ac.il.
Meital Gal-TanamyMolecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Electronic address: Meital.Tanamy@biu.ac.il.
Sefi VernickDepartment of Sensing, Information and Mechanization Engineering, Institute of Agricultural Engineering, ARO Volcani Center, 68 Hamaccabim Rd, Rishon lezion, 5025001, Israel. Electronic address: sefi@volcani.agri.gov.il.
Bar-Ilan University · ILAgricultural Research Organization · ILHebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has highlighted the need for reliable and accurate diagnostic tools that provide quantitative results at the point of care. Real-time RT-PCR requires large laboratories, a skilled workforce, complex and costly equipment, and labor-intensive sample processing. Despite tremendous efforts, scaling up RT-PCR tests is seemingly unattainable. To date, hundreds of millions of COVID-19 tests have been performed globally, but the demand for timely, accurate testing continues to outstrip supply. Antigen-based rapid diagnostic testing is emerging as an alternative to RT-PCR. However, the performance of these tests, namely their sensitivity, is still inadequate. To overcome the limitations of currently employed diagnostic tests, new tools that are both sensitive and scalable are urgently needed. We have developed a miniaturized electrochemical biosensor based on the integration of specific monoclonal antibodies with a biochip and a measurement platform, and applied it in the detection of Spike S1 protein, the binding protein of SARS-CoV-2. Using electrochemical impedance spectroscopy, quantitative detection of sub-nanomolar concentrations of Spike S1 was demonstrated, exhibiting a broad detection range. To demonstrate the applicability of the biosensor, we have further developed a SARS-CoV-2 pseudovirus based on Spike protein-pseudo-typed VSV platform. Specific detection of different concentrations of pseudovirus particles was feasible in <30 min. This new tool may largely contribute to the fight against COVID-19 by enabling intensive testing to be performed and alleviating most of the hurdles that plague current diagnostics.

Indexed as

COVID-19Vesicular StomatitisAnimalsDiagnostic Tests, RoutineHumansPandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusSpike Glycoprotein, CoronavirusCOVID-19Electrochemical impedance spectroscopyImmunosensorsRapid diagnostic testingSARS-CoV-2 pseudovirus

Identifiers

PMID34920254
PMCPMC8667521
OpenAlexW4200389856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.